Linagliptin

(Tradjenta®)

Linagliptin

Drug updated on 11/9/2023

Dosage FormTablet (oral; 5 mg)
Drug ClassDipeptidyl peptidase-4 (DPP-4) inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Product Monograph / Prescribing Information

Document TitleYearSource
Tradjenta (linagliptin) Prescribing Information.2023Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Comparative efficacy and safety of glucose-lowering drugs in children and adolescents with type 2 diabetes: A systematic review and network meta-analysis.2022Frontiers in Endocrinology
Safety and tolerability of linagliptin in Asians with type 2 diabetes: a pooled analysis of 4457 patients from 21 randomized, double-blind, placebo-controlled clinical trials.2022Expert Opinion on Drug Safety
Comparison of gliclazide vs linagliptin on hypoglycemia and cardiovascular events in type 2 diabetes mellitus: a systematic review.2022World Journal of Diabetes
Bullous pemphigoid and dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized controlled trials.2020Endocrine
Fixed-dose combination of empagliflozin and linagliptin for the treatment of patients with type 2 diabetes mellitus: A systematic review and meta-analysis.2020Diabetes Obesity and Metabolism
Risk of cancer in patients treated with dipeptidyl peptidase-4 inhibitors: an extensive meta-analysis of randomized controlled trials.2020Acta Diabetologica
The effect of dipeptidyl peptidase-4 inhibitors on macrovascular and microvascular complications of diabetes mellitus: a systematic review.2020Current Therapeutic Research
The effect of DPP-4i on endothelial function and arterial stiffness in patients with type 2 diabetes: a systematic review of randomized placebo-controlled trials.2020Current Pharmaceutical Design
Association between medication use and bullous pemphigoid. A systematic review and meta-analysis.2020JAMA Dermatology
Dipeptidyl peptidase-4 inhibitors and bullous pemphigoid: a systematic review and adjusted meta-analysis.2020Australasian Journal of Dermatology
Effects of sodium-glucose cotransporter 2 inhibitor monotherapy on weight changes in patients with type 2 diabetes mellitus: a Bayesian network meta-analysis.2019Clinical Therapeutics
Risk of fractures associated with dipeptidyl peptidase-4 inhibitor treatment: a systematic review and meta-analysis of randomized controlled trials.2019Diabetes Therapy
The efficacy and safety of dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a Bayesian network meta-analysis of 58 randomized controlled trials.2019Acta Diabetologica
Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.2018Cochrane Database of Systematic Reviews
Linagliptin safety profile: a systematic review.2018Primary Care Diabetes

Clinical Practice Guidelines